Table 4 FDA approved biosimilars
Date of biosimilar FDA approval | Biosimilar product | Original product | Active substance |
|---|---|---|---|
06 March 2015 (U.S. Department of Health and Human Services and Food and Drug Administration 2016a) | Zarxio | Neupogen | Filgrastim |
05 April 2016 (U.S. Department of Health and Human Services and Food and Drug Administration 2016b) | Inflectra | Remicade | Infliximab |
30 August 2016 (U.S. Department of Health and Human Services and Food and Drug Administration 2016c) | Erelzi | Enbrel | Etanercept |
23 September 2016 (U.S. Department of Health and Human Services and Food and Drug Administration 2016d) | Amjevita | Humira | Adalimumab |